Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer

Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer

Blog Article

Background: Treatment of recurrent platinum-resistant high grade serous ovarian cancer (HGSOC) remains a challenge.Novel treatment options for recurrent disease are an unmet need.Case: A 69-year-old with recurrent, metastatic, platinum-resistant HGSOC overexpressing TROP2 experienced a significant response to the antibody-drug conjugate (ADC) sacituzumab govitecan after multiple failed lines of chemotherapy and targeted treatment.Following sacituzumab govitecan treatment she experienced a confirmed partial response as well as a return of CA-125 to osborne hog feeders for sale baseline.

Having now completed 8 cycles (ie, over 6 months of treatment), her disease continues to demonstrate a response to sacituzumab govitecan treatment.The ADC has been well tolerated at a dose of 10 mg/kg with no dose-limiting toxicity or need for dose reductions.Conclusion: Sacituzumab govitecan may represent a treatment option for platinum-resistant/recurrent HGSOC that have previously failed prior lines of chemotherapy.Clinical trials with sacituzumab govitecan in platinum-resistant ovarian cancer patients weleda skin food 75ml best price are currently ongoing (https://classic.

clinicaltrials.gov/ct2/show/NCT06028932).